Index Ventures launches pharma co. as acquisition bait
Index Ventures is partnering with Mountain View, Calif.-based biotech firm Amunix to launch Versartis, a pharmaceutical company that will market diabetes and metabolic disease treatments, reports VentureWire. Each partner owns half of the new company, which also just received $11 million from Index in first-round funding.
The team says it only needs to push one of the drugs through phase one clinical trials to be well-positioned for a lucrative acquisition. While they predict this will take… Continue Reading